Skip to main
IMUX

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immunic Inc. has demonstrated promising clinical results in multiple sclerosis (MS) through its Phase 2 CALLIPER and EMPhASIS trials, showing significant reductions in disability worsening and improvements in MRI markers, indicating potential efficacy for its lead candidate, vidofludimus calcium. The company's focus on a selective approach to immunotherapy, particularly its small molecule products aimed at chronic inflammatory diseases, addresses critical unmet needs in the therapeutic landscape. Furthermore, the anticipated Phase 3 ENSURE trials, alongside supportive long-term safety and efficacy data, bolster investor confidence in Immunic's ability to successfully navigate late-stage development and capture market opportunities.

Bears say

Immunic Inc. faces significant financial challenges that contribute to a negative outlook on its stock. The company's recent capital raises, including a $5 million direct offering and a $65 million public offering, are overshadowed by a substantial cash burn of $20 million in R&D expenses and $6 million in general and administrative costs within a single quarter. Furthermore, risks associated with the potential failure of their developmental candidates to meet commercial revenue projections and the ongoing need for capital resources to sustain operations deepen the concerns regarding the company's future financial stability.

Immunic Inc (IMUX) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Immunic Inc (IMUX) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.